Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan in Heart Failure with Preserved Ejection Fraction (CHARM-Preserved)
NCT00634712Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 1999
- Primary completion
- May 2003
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
A Phase 3 trial of candesartan in heart failure with preserved ejection fraction (HFpEF), sponsored by AstraZeneca. Started Jun 1999; status: completed.
02
Drugs
candesartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00634712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634712.